Physicians at NewYork-Presbyterian’s Congenital Heart Centre – a combined program of Morgan Stanley Children’s Hospital and NewYork-Presbyterian Komansky Children’s Hospital – see not just a lot of cases, but a lot of complex cases. A nuance that allows paediatric cardiac surgeons and interventional cardiologists to think outside of the box when leading clinical initiatives and conducting groundbreaking research.
First CICU for newborns with CHD
As the first cardiac intensive care unit (CICU) in the nation exclusively dedicated to the care of newborn infants with congenital heart disease (CHD) – including those in need of and recovering from a heart transplant – NewYork-Presbyterian is especially adept at caring for babies with some of the most complex and challenging cases. From the beds to the medical and surgical equipment, everything in the unit is designed for the tiniest newborns.
Advanced paediatric heart care
Our renowned paediatric cardiology and cardiac surgery experts are committed to an integrated approach to the treatment of complex heart conditions providing the safest, most advanced paediatric heart care – from the prenatal and newborn period, through adolescence to adulthood. Our smallest patient to undergo cardiac surgery weighed just 500 grams (1.1 pound). For babies with complex heart conditions, our high-risk OB team collaborates with cardiovascular surgeons, interventional cardiologists, cardiologists as well as multiple subspecialties to provide advanced care.
“We offer the entire range of surgical treatment options for complex congenital aortic valve disease,” says Emile Bacha, MD, Chief of Congenital and Pediatric Cardiac Surgery at NewYork-Presbyterian Morgan Stanley Children’s Hospital.
Lifesaving support options
Mechanical assist devices are needed in up to 50% the paediatric congenital heart patient population at NewYork-Presbyterian, illustrating the complexity and acuity of cases. As one of 7 vanguard sites across the country participating in the NIH-funded PumpKIN trial, we are examining the safety and efficacy of the Jarvik 2015, a ventricular assist device aimed to support the smallest of our patients while minimizing complications encountered with other systems of mechanical support. As part of the PumpKIN trial, we successfully bridged a toddler with dilated cardiomyopathy to heart transplant.
Paediatric heart transplant
The world’s first successful heart transplant in a child was performed at Columbia Presbyterian Medical Center in June 1984 on a four-year-old boy with complex congenital heart disease. Since then, more than 550 children – ranging in age from less than one year to 24 years old – have received new hearts at what is now NewYork-Presbyterian Morgan Stanley Children’s Hospital. Today, NewYork-Presbyterian is one of the highest volume paediatric heart transplant centres in the United States with outcomes exceeding national and local benchmarks, as reported by United Network for Organ Sharing (2019).
We are renowned for successfully transplanting children with complex heart conditions – many of whom are turned down by other institutions and programs. With nearly four decades of success, many of our heart transplant recipients are surviving 30 years with their heart transplant and now have families of their own.
We offer the entire range of surgical treatment options for complex congenital aortic valve disease.
– Dr. Emile Bacha
Paediatric interventional cardiology
Many of the paediatric interventional procedures at NewYork-Presbyterian’s Congenital Heart Center have moved from our operating rooms to our paediatric catheterization laboratories, offering our littlest patients’ nonsurgical options to decrease the number of open-heart surgeries throughout their lifetime. As one of the first in the United States to successfully implant the Alterra adaptive pre-stent in patients with congenital heart disease, NewYork-Presbyterian Morgan Stanley Children’s Hospital is participating in the pivotal Multicenter Study of Congenital Pulmonic Valve Dysfunction studying the SAPIEN 3 THV with the Alterra adaptive pre-stent. The self-expanding, partially covered stent is designed to reduce the size of large right ventricular outflow tracts and decrease the total number of surgeries a paediatric patient may need over his/her lifetime.
Contact
NewYork-Presbyterian MENA
Representative: Issam Ramadan
Cell: +971 56 624 2588
Email: isr9012@nyp.org
NY Main Office: +1 212 746 9100
Email: globalservices@nyp.org
